Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
March 5, 2007
- More Radiologists, Radiotherapy Equipment Specialists Needed: Prof. Nakagawa
March 5, 2007
- CMIC to Go to the West to Promote Japan-Centered Clinical Trials
February 26, 2007
- R&D NEWS IN BRIEF
February 26, 2007
- Roche Diagnostics Aims for 7.1% Growth in Sales in Bearish Market
February 26, 2007
- 13 Medical Devices Selected for Priority Review
February 26, 2007
- MEDICAL DEVICE NEWS IN BRIEF
February 26, 2007
- Korosho Again Calls For Early Price Settlement
February 26, 2007
- Daiichi Sankyo Gears Up to Become Global Drug Discovery Company
February 26, 2007
- REGULATORY NEWS IN BRIEF
February 26, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 26, 2007
- OTC Drugs That Meet Today's Needs Are Necessary: Mr Kurokawa
February 26, 2007
- NEW PRODUCT
February 26, 2007
- METI to Start Health Information Platform Initiative
February 26, 2007
- Kyowa Hakko Achieves Personnel Cost Cutting Target Ahead of Schedule
February 26, 2007
- JPA Working Out Clear Position Toward Promotion of GE Drugs
February 26, 2007
- Intage Surveying Doctors on MR Calls and Their Impact
February 26, 2007
- No Marked Rise in Share of Generics from Jun. to Oct. 2006
February 26, 2007
- BUSINESS NEWS IN BRIEF
February 26, 2007
- Toyama Prefecture Tests Generics from Makers Under Its Control
February 26, 2007
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…